Leukemia Research
Volume 29, Issue 6 , Pages 665-671 , June 2005

Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival

  • Xavier Leleu

      Affiliations

    • Service des Maladies du Sang, CHU Lille, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 3 20 44 57 13; fax: +33 3 20 44 47 08.
    • ,
  • Franck Genevieve

      Affiliations

    • Laboratoire d’Hematologie and UPRES EA-3863 “analyse des déterminants de la réponse immunitaire”, CHU Angers, France
    • ,
  • Romain Guieze

      Affiliations

    • Service des Maladies du Sang, CHU Lille, France
    • ,
  • Alain Duhamel

      Affiliations

    • Service de Biostatistique, CHU Lille, France
    • ,
  • Joris Andrieux

      Affiliations

    • Service de Genetique Medicale, CHU Lille, France
    • ,
  • Celine Berthon

      Affiliations

    • Service des Maladies du Sang, CHU Lille, France
    • ,
  • Alban Godon

      Affiliations

    • Laboratoire d’Hematologie and UPRES EA-3863 “analyse des déterminants de la réponse immunitaire”, CHU Angers, France
    • ,
  • Sophie Prat-Lesaffre

      Affiliations

    • Laboratoire d’Hematologie and UPRES EA-3863 “analyse des déterminants de la réponse immunitaire”, CHU Angers, France
    • ,
  • Stephane Depil

      Affiliations

    • Service des Maladies du Sang, CHU Lille, France
    • ,
  • Jean-Luc Lai

      Affiliations

    • Service de Genetique Medicale, CHU Lille, France
    • ,
  • Thierry Facon

      Affiliations

    • Service des Maladies du Sang, CHU Lille, France
    • ,
  • Marc Zandecki

      Affiliations

    • Laboratoire d’Hematologie and UPRES EA-3863 “analyse des déterminants de la réponse immunitaire”, CHU Angers, France
    • ,
  • On behalf of the Intergroupe Francophone du Myelome (IFM)

Received 26 October 2004 ,Revised 16 December 2004 ,Accepted 22 December 2004.

References 

  1. Greipp PR, Katzmann JA, O’Fallon WM, Kyle RA. Value of beta-2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988;72:219–223
  2. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2-microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733–737
  3. Fonseca R, Conte G, Greipp PR. Laboratory correlates in multiple myeloma: how useful for prognosis?. Blood Rev. 2001;15:97–102
  4. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4:379–398
  5. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849
  6. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  7. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99:2185–2191
  8. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, et al. The recurrent IgH translocations are highly associated with non hyperdiploid variant multiple myeloma. Blood. 2003;102:2562–2567
  9. Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood. 2003;101:4998–5006
  10. Kuss LG. Diagnostic cytology and its histopathologic bases. 3rd ed.. Philadelphia, PA: J.B. Lippincott; 1977;
  11. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87:342–355
  12. Buss DH, Reynolds GD, Cooper MR. Multiple myeloma associated with multilobated plasma cell nuclei. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;55:287–292
  13. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–57.
  14. Grosbois B, Mary JY, Michaux JL, Facon T, Laporte JP, Euller-Ziegler L, et al. Continuous or sequential melphalan in combination with interferon alpha-2a and prednisone in patients with multiple myeloma. Blood. 1993;82:263a
  15. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97
  16. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200mg/m(2) melphalan and 8 Gy total body irradiation plus 140mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731–735
  17. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood. 1995;85:2490–2497
  18. Zandecki M, Bernardi F, Lai JL, Facon T, Izydorczyk V, Bauters F, et al. Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study. Cancer Genet Cytogenet. 1994;74:115–119
  19. Zandecki M, Obein V, Bernardi F, Soenen V, Flactif M, Lai JL, et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol. 1995;90:693–696
  20. Lokhorst HM, Boom SE, Terpstra W, Roholl P, Gerdes J, Bast BJ. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67. Br J Haematol. 1988;69:477–481
  21. Kaplan E, Meier P. Non parametric estimation from incomplete observations. Am J Stat Assoc. 1958;53:457–481
  22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  23. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;R34:187
  24. Davies M, Fleiss JL. Measuring agreement for multinomial data. Biometrics. 1982;38:1047–1051
  25. Kurabayashi H, Miyawaki S, Murakami H, Nemoto K, Sawamura M, Kubota K, et al. Ultrastructure of multinucleated giant myeloma cells: report of one case. Am J Hematol. 1989;31:284–285
  26. Zukerberg LR, Ferry JA, Conlon M, Harris NL. Plasma cell myeloma with cleaved, multilobated, and monocytoid nuclei. Am J Clin Pathol. 1990;93:657–661
  27. Sivakumaran M, Parker A, Murphy P, Colloby P, Short M, Mitchell VE. Multilobulated, multinucleated multiple myeloma. Br J Haematol. 1992;81:622–624
  28. Greipp PR, Raymond NM, Kyle RA, O’Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985;65:305–310
  29. Greipp PR. Toward a morphologic classification of multiple myeloma?. Leuk Res. 1999;23:1141–1142
  30. Jones D, Bhatia VK, Krausz T, Pinkus GS. Crystal-storing histiocytosis: a disorder occurring in plasmacytic tumors expressing immunoglobulin kappa light chain. Hum Pathol. 1999;30:1441–1448
  31. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, et al. Plasmablastic morphology—an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501–2507
  32. Goasguen JE, Zandecki M, Mathiot C, Scheiff JM, Bizet M, Ly-Sunnaram B, et al. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res. 1999;23:1133–1140
  33. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia. 2003;17:2032–2035
  34. Carter A, Hocherman I, Linn S, Cohen Y, Tatarsky I. Prognostic significance of plasma cell morphology in multiple myeloma. Cancer. 1987;60:1060–1065
  35. Weh HJ, Bartl R, Seeger D, Selbach J, Kuse R, Hossfeld DK. Correlations between karyotype and cytologic findings in multiple myeloma. Leukemia. 1995;9:2119–2122
  36. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579–1583
  37. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–4575
  38. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008–4010
  39. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925–1930
  40. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999;13:79–90
  41. Bataille R, Grenier J, Sany J. Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma. Anticancer Res. 1987;7:513–515
  42. Milla F, Oriol A, Aguilar JL, Aventin A, Ayats R, Alonso E, et al. Usefulness and reproducibility of cytomorphologic evaluations to differentiate myeloma from monoclonal gammopathy of unknown significance. Am J Clin Pathol. 2001;115:127–135

PII: S0145-2126(05)00020-2

doi: 10.1016/j.leukres.2004.12.002

Leukemia Research
Volume 29, Issue 6 , Pages 665-671 , June 2005

Article Tools

* Image Usage & Resolution